Poolbeg Pharma PLC (AIM:POLB) said the US Patent Office has issued a Notice of Allowance for its immunomodulator II patent.
This advancement marks a critical step towards the formal patent grant for POLB 001, a phase II-ready p38 MAP kinase inhibitor with the potential to treat hypercytokinaemia (cytokine storm) across various diseases.
"POLB 001 has the potential to make breakthrough cancer immunotherapies more accessible to the patients that need them by enabling safer and broader use of these cancer treatments in an outpatient setting," said CEO Jeremy Skillington.
"I am excited by the potential of POLB 001 to positively impact global health, it has a compelling data package and there is strong unmet need for an effective therapy for cancer immunotherapy-induced cytokine release syndrome with the market potential in this setting alone exceeding US$10 billion."